Vir Biotechnology, Inc. (VIR)SB Investment Advisers (UK) Ltd reduced its stake -3.57M shares

13.1M

Shares reported · -3.57M vs prior quarter

0.79%

Disclosed portfolio weight

$79.1M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

What came next

1. Feb 19, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 2 more items)
2. Feb 25, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
3. Mar 4, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 4, 2026, the Board of Directors of Vir Biotechnology, Inc. (Vir Bio) appointed Marianne De Backer, M.Sc., Ph.D., MBA, Vir Bio’s Chief Executive Officer and principal executive officer, to the additional position of President.”
4. Apr 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 7, 2026, Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (the Company), informed the Company that he will be stepping down from his role, effective April 24, 2026.”
5. May 6, 2026Company filing · Form 8-K · ResultsReported its results
6. May 25, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.”
7. Jun 9, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 9, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from seven to eight members and the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve on the Board as a Class III director until the Company’s 2028 annual…”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Vir Biotechnology, Inc.

OQRO holds no insider, Congress, fund or contract record for Vir Biotechnology, Inc. dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VIR page.

How this filing works

• SEC Form 13F

Other disclosures at Vir Biotechnology, Inc.

• SEC Form 13F-HRMay 18, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Sep 3, 2025
• SEC Form 13F-HRAug 14, 2025
• SEC Form 4Aug 4, 2025
• SEC Form 4Jul 17, 2025

Everything OQRO holds on this company is on its VIR page.